Join Us On Facebook.
Follow us on Twitter.
Clearview News Wire
Copyright © 2007 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
Inhaled drug may prevent lung cancer: study
Last Updated: 2010-05-18 16:05:48 -0400 (Reuters Health)May 19, 2010
WASHINGTON (Reuters) - A drug approved to treat a range of conditions may also work to prevent lung cancer in people who have given up smoking, U.S. researchers reported on Tuesday.The drug, called iloprost, is approved in inhaled forms to treat pulmonary hypertension, when blood pools near the lungs, a connective tissue disease called scleroderma and a nerve condition called Raynaud's phenomenon.
Dr. Robert Keith of the Denver Veterans Affairs Medical Center and colleagues tested an oral version to see if it might prevent lung cancer in smokers and former smokers.
"Oral iloprost showed promise for preventing lung cancer in former, but not current, smokers in a phase II clinical trial," they wrote in a summary presented to a meeting of the American Thoracic Society in New Orleans.
Iloprost is a version of prostacyclin, a drug in the prostaglandin class that prevents lung cancer in mice.
Keith, who has been testing several drugs to prevent lung cancer, looked at biopsies taken from the lungs of 125 current and former smokers.
They treated half with placebo and half with iloprost, and then performed bronchoscopy examinations to assess precancerous changes in the lungs.
Six months later, "former smokers showed significant improvements on all measures, indicating that treatment with iloprost may reduce the risk of developing lung cancer among former smokers," the researchers said.
"Interestingly, current smokers did not show any significant improvements," they added.
"Oral iloprost significantly improves endobronchial dysplasia in former smokers and deserves further study to determine if it can prevent the development of lung cancer."
Swiss drug maker Actelion markets inhaled iloprost under the brand name Ventavis.
It is also sold in an intravenous form under the trade name Ilomedin by Schering, acquired by Merck.
In April, researchers said a natural supplement derived from food, called myo-inositol, seems to stop the precancerous changes that lead to lung cancer.
Cigarette smoke causes 90 percent of all cases of lung cancer, which kills 1.2 million people a year globally. But only about 10 percent of smokers ever develop lung cancer, although they often die of other causes like heart disease, stroke or emphysema.
Tweet
Other Articles:
- February 3, 2012
- Senators urge Komen to reconsider funding decision
- February 1, 2012
- Eating fish tied to lower risk of colon polyps
- January 31, 2012
- Kids seek tans, use less sunscreen as they Age
- January 18, 2012
- FDA approves BTG's drug for cancer toxicity
- January 5, 2012
- Argentina's Fernandez undergoes cancer surgery
- December 20, 2011
- Vitamin D has mixed effects on cancer, broken bones
- December 13, 2011
- Memory issues after cancer may not be due to chemo
- December 8, 2011
- Quicker radiation therapy doubles mastectomy risk
- December 7, 2011
- Prostate cancer hormonal therapy cuts deaths: report
- November 17, 2011
- More fruit tied to lower risk of uterine fibroids
- November 15, 2011
- Brain scan study finds evidence of 'chemo brain'
- November 9, 2011
- No link between selenium, lower lung cancer risk
- November 8, 2011
- Singer Andy Williams reveals he has cancer
- November 7, 2011
- More evidence obesity tied to colon cancer
- November 4, 2011
- More evidence obesity tied to colon cancer
- October 31, 2011
- Heavy drinking tied to higher stomach cancer risk